XSHE
300642
Market cap476mUSD
Oct 09, Last price
21.21CNY
1D
7.88%
1Q
69.00%
IPO
0.15%
Name
Tellgen Corp
Chart & performance
P/E
959.28
P/S
9.46
EPS
0.02
Div yield, %
0.76%
Shrs. gr., 5y
-0.16%
Rev. gr., 5y
-11.08%
Revenues
364m
-16.70%
Net income
4m
-89.61%
CFO
143m
-12.99%
Dividend
Sep 03, 20260.05 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Tellgen Corporation is dedicated to the creation, manufacturing, and supply of in-vitro diagnostic (IVD) solutions, serving both the Chinese domestic market and a global clientele. Their extensive product catalog includes cancer detection markers, test kits for human papilloma virus (HPV), ToRCH diagnostic assays, Y-chromosome microdeletion screening kits, and sophisticated multiplex immunoassay systems. The company, founded in 2003, operates from its headquarters in Shanghai, China.
Key people
Songtao Li
Finance Director · since 2023
Jian'er Yao
Chairman of the Board, General Manager · since 2015
Gang Chen
Deputy General Manager · since 2025
Ye Sheng
Deputy General Manager · since 2020
Xiaoqing Wang
Deputy General Manager, Secretary of the Board, Director · since 2020
Enhuai Yang
Deputy General Manager, Director · since 2020
Zhangfu Yu
Director · since 2019
Shaoxiong Chen
Independent Director · since 2023
Wei Yu
Independent Director · since 2020
Jiaxiang Zhao
Independent Director · since 2023
Headquarters & legal address
中国（上海）自由贸易试验区碧波路572弄115号1幢
静安区, SH 200000
CN
静安区, SH 200000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||
Revenues | |||||||||||
Cost of revenue | |||||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | |||||||||||
NOPBT Margin | |||||||||||
Operating Taxes | |||||||||||
Tax Rate | |||||||||||
NOPAT | |||||||||||
Net income | |||||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | |||||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | |||||||||||
Long-term debt | |||||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | |||||||||||
Net debt | |||||||||||
| Cash flow | |||||||||||
Cash from operating activities | |||||||||||
CAPEX | |||||||||||
Cash from investing activities | |||||||||||
Cash from financing activities | |||||||||||
FCF | |||||||||||
| Balance | |||||||||||
Cash | |||||||||||
Long term investments | |||||||||||
Excess cash | |||||||||||
Stockholders' equity | |||||||||||
Invested Capital | |||||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | |||||||||||
Price | |||||||||||
Market cap | |||||||||||
EV | |||||||||||
EBITDA | |||||||||||
EV/EBITDA | |||||||||||
Interest | |||||||||||
Interest/NOPBT | |||||||||||